The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.
Eve T. Rodler
No relevant relationships to disclose
Julie Gralow
No relevant relationships to disclose
Brenda F. Kurland
No relevant relationships to disclose
Melissa Griffin
No relevant relationships to disclose
Rosa Yeh
No relevant relationships to disclose
John A. Thompson
No relevant relationships to disclose
Peggy Porter
No relevant relationships to disclose
Elizabeth M. Swisher
No relevant relationships to disclose
Vijayakrishna K. Gadi
No relevant relationships to disclose
Larissa A. Korde
No relevant relationships to disclose
Hannah M. Linden
No relevant relationships to disclose
Georgiana Kehr Ellis
No relevant relationships to disclose
Stacie Peacock Shepherd
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie (B)
Vincent L. Giranda
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Xiaoyu Chai
No relevant relationships to disclose
Jeannette Hammond
No relevant relationships to disclose
Reina Hibbert
No relevant relationships to disclose
Bojana Askovich
No relevant relationships to disclose
Jennifer M. Specht
No relevant relationships to disclose